Publications by authors named "Mathieu Joseph Francois Crupi"
Article Synopsis
- Targeted antineoplastic immunotherapies face challenges like resistance due to the absence of specific targets or loss of antigens, limiting their effectiveness in treating tumors.
- Researchers developed an oncolytic rhabdovirus, VSVΔ51, designed to express a truncated version of the HER2 antigen, which allows for effective targeting of tumors using the antibody-drug conjugate trastuzumab emtansine.
- The study also combines VSVΔ51-HER2T with a vaccinia virus for a dual-virus treatment approach, showing strong potential for curative effects in living models, suggesting a promising method for improving the tumor microenvironment and enhancing treatment options.
